Publication: A randomised controlled trial of the efficacy and safety of 0.25% desoximetasone cream (Topoxy) compared with 0.25% desoximetasone cream (Topicorte) for the treatment of scalp psoriasis
6
Issued Date
2020-09-01
Resource Type
ISSN
22288082
Other identifier(s)
2-s2.0-85089804291
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Siriraj Medical Journal. Vol.72, No.5 (2020), 371-379
Suggested Citation
Leena Chularojanamontri, Narumol Silpa-archa, Pichanee Chaweekulrat, Chayanee Likitwattananurak, Puncharas Weerasubpong, Natchaya Junsuwan, Norramon Charoenpipatsin, Chanisada Wongpraparut A randomised controlled trial of the efficacy and safety of 0.25% desoximetasone cream (Topoxy) compared with 0.25% desoximetasone cream (Topicorte) for the treatment of scalp psoriasis. Siriraj Medical Journal. Vol.72, No.5 (2020), 371-379. doi:10.33192/SMJ.2020.50 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/59175
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A randomised controlled trial of the efficacy and safety of 0.25% desoximetasone cream (Topoxy) compared with 0.25% desoximetasone cream (Topicorte) for the treatment of scalp psoriasis
Other Contributor(s)
Abstract
© 2020 Faculty of Medicine Siriraj Hospital, Mahidol University. Objective: To compare the efficacy and safety of a generic desoximetasone cream (Topoxy) with the reference form, Topicorte, for the treatment of scalp psoriasis. Methods: A randomised, double-blind, controlled study was conducted. Altogether, 105 patients with psoriasis lesions covering more than 10% of the scalp were randomised into three groups. The first, second and third groups received a placebo, Topoxy and Topicorte, respectively. The scalp psoriasis severities were assessed at weeks 0, 2, 4 and 8, using the Investigator Global Assessment (IGA) scale and Total Sign Score (TSS). The safety profiles of the products were assessed by the patients and physicians. Results: Topoxy and Topicorte were significantly more effective than the placebo in achieving at least a two-grade improvement in the IGA score from baseline at weeks 2, 4 and 8, and there were no significant differences between Topoxy and Topicorte. The TSS of both creams were significantly lower than that of the placebo at weeks 2, 4 and 8. All patients tolerated well to the therapy. Conclusion: Topoxy and Topicorte had comparable efficacies for scalp psoriasis. The medications were superior to the placebo in all parameters, and had a good safety profile.